Roper Technologies Sees Q4 Adj. Earnings Below Market View; Updates FY21 Forecast - Quick Facts

While announcing higher third-quarter results, diversified technology company Roper Technologies, Inc. (ROP) said Friday that it expects fourth-quarter adjusted earnings per share from continuing operations of $3.62 to $3.66.

On average, 11 analysts polled by Thomson Reuters expect earnings of $3.96 per share for the quarter. Analysts' estimates typically exclude special items.

Further, the company now expects expects fiscal 2021 adjusted earnings per share from continuing operations of $14.08 to $14.12. On a comparable basis, new guidance would be $15.26 - $15.30.

The previous full-year outlook was adjusted earnings per share of $15.00 - $15.20, including the businesses now reported in discontinued operations.

Analysts expect earnings of $15.2 per share for the full year.

Neil Hunn, Roper Technologies' President and CEO, said, "Over the past several months, we announced three strategic divestitures that will accelerate the transformation of our portfolio. We anticipate redeploying the net proceeds from these transactions toward our robust pipeline of high-quality acquisition opportunities, enabling us to further enhance the quality of the enterprise."

In pre-market activity on the NYSE, Roper shares were losing around 1.4 percent to trade at $474.68.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Teleflex Inc., a provider of medical technologies for critical care and surgery, is recalling Arrow-Trerotola Over-The-Wire PTD Kit Percutaneous Thrombolytic Device: 7FR, the U.S. Food and Drug Administration said. The Arrow-Trerotola Percutaneous Thrombolytic Device or PTD Catheter, in conjunction with the Arrow Rotator Drive Unit, permits mechanical declotting of native arterio-venous or AV... Privately-held biotechnology company On Target Laboratories, Inc. announce that the U.S. Food and Drug Administration or FDA, has approved Cytalux (pafolacianine) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Cytalux is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively. The Federal Trade Commission or FTC has ordered Walmart, Amazon, Kroger and certain other large wholesalers and suppliers to provide information to help it study causes of supply chain disruptions. The agency has launched an inquiry to find the reasons for empty shelves and exorbitant prices. Along with Walmart, Amazon.com, and Kroger, the order has been sent to C&S Wholesale Grocers, Associated..
Follow RTT